Healthcare provider profile · identity verified

Parvez Razzaque Memon, MD

Allopathic & Osteopathic Physicians|Internal Medicine · BAKERSFIELD, CA · NPI 1144329038

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Parvez Razzaque Memon, MD received $136.08 in general payments during 2025 across 7 reported records.

GlaxoSmithKline, LLC. accounted for 34.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 5 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Trelegy Ellipta.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 290 claims for Jardiance by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Trelegy Ellipta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$136.08

7 reported records · 5 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$46.54	34.2%	2	2025
Bayer Healthcare Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$43.26	31.8%	2	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$16.58	12.2%	1	2025
Eisai Inc.	Unresolved — no canonical attribution shown	$14.94	11.0%	1	2025
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$14.76	10.8%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$136.08	7

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
TRELEGY ELLIPTA Normalized: trelegy ellipta	Drug	GlaxoSmithKline, LLC.	$46.54	2	2025
Source payment records 2025-01-26 · GlaxoSmithKline, LLC. · $21.92 · Open Payments source 2025-04-21 · GlaxoSmithKline, LLC. · $24.62 · Open Payments source
Kerendia Normalized: kerendia	Drug	Bayer Healthcare Pharmaceuticals Inc.	$43.26	2	2025
Source payment records 2025-09-02 · Bayer Healthcare Pharmaceuticals Inc. · $23.85 · Open Payments source 2025-10-07 · Bayer Healthcare Pharmaceuticals Inc. · $19.41 · Open Payments source
AREXVY Normalized: arexvy	Biological	GlaxoSmithKline, LLC.	$21.92	1	2025
Source payment records 2025-01-26 · GlaxoSmithKline, LLC. · $21.92 · Open Payments source
Leqembi Normalized: leqembi	Drug	Eisai Inc.	$14.94	1	2025
Source payment records 2025-06-16 · Eisai Inc. · $14.94 · Open Payments source
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$14.76	1	2025
Source payment records 2025-09-08 · Boehringer Ingelheim Pharmaceuticals, Inc. · $14.76 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
AREXVY arexvy	2025	Arexvy	2024	18	exact normalized	Medicare Part D
JARDIANCE jardiance	2025	Jardiance	2024	290	exact normalized	Medicare Part D
TRELEGY ELLIPTA trelegy ellipta	2025	Trelegy Ellipta	2024	161	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	139	30
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	LOKELMA open payments reported associated product	CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624	Lokelma · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	290	36
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	AREXVY open payments reported associated product	CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445	Arexvy · 2024 Exact normalized brand match · 1 Part D row	18	18
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	161	39

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	2352	311
Levothyroxine Sodium	Levothyroxine Sodium	1478	192
Furosemide	Furosemide	1385	147
Gabapentin	Gabapentin	1377	194
Pantoprazole Sodium	Pantoprazole Sodium	1108	141
Amlodipine Besylate	Amlodipine Besylate	882	149
Eliquis	Apixaban	752	90
Donepezil Hcl	Donepezil Hcl	716	75
Tamsulosin Hcl	Tamsulosin Hcl	707	100
Metoprolol Tartrate	Metoprolol Tartrate	704	78
Metformin Hcl	Metformin Hcl	672	114
Famotidine	Famotidine	636	81
Mirtazapine	Mirtazapine	606	51
Clopidogrel	Clopidogrel Bisulfate	584	70
Potassium Chloride	Potassium Chloride	578	78
Losartan Potassium	Losartan Potassium	577	112
Metoprolol Succinate	Metoprolol Succinate	548	95
Memantine Hcl	Memantine Hcl	531	63
Lisinopril	Lisinopril	519	107
Carvedilol	Carvedilol	468	68
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	439	78
Trazodone Hcl	Trazodone Hcl	414	54
Citalopram Hbr	Citalopram Hydrobromide	411	51
Irbesartan	Irbesartan	390	46
Omeprazole	Omeprazole	370	93
Meloxicam	Meloxicam	352	59
Nifedipine Er	Nifedipine	323	41
Allopurinol	Allopurinol	319	50
Ropinirole Hcl	Ropinirole Hcl	312	35
Escitalopram Oxalate	Escitalopram Oxalate	294	39
Jardiance	Empagliflozin	290	36
Levetiracetam	Levetiracetam	285	23
Midodrine Hcl	Midodrine Hcl	278	39
Carbidopa-Levodopa	Carbidopa/Levodopa	269	13
Hydralazine Hcl	Hydralazine Hcl	246	34
Baclofen	Baclofen	244	24
Myrbetriq	Mirabegron	235	20
Amiodarone Hcl	Amiodarone Hcl	226	40
Tramadol Hcl	Tramadol Hcl	225	88
Duloxetine Hcl	Duloxetine Hcl	217	30
Sertraline Hcl	Sertraline Hcl	215	29
Oxybutynin Chloride	Oxybutynin Chloride	208	20
Xarelto	Rivaroxaban	206	19
Simvastatin	Simvastatin	203	43
Alendronate Sodium	Alendronate Sodium	201	53
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	197	53
Tizanidine Hcl	Tizanidine Hcl	188	36
Rosuvastatin Calcium	Rosuvastatin Calcium	186	48
Lorazepam	Lorazepam	180	54
Cephalexin	Cephalexin	172	93
Finasteride	Finasteride	167	30
Clonidine Hcl	Clonidine Hcl	165	39
Lovastatin	Lovastatin	165	15
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	161	39
Buspirone Hcl	Buspirone Hcl	157	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	156	72
Quetiapine Fumarate	Quetiapine Fumarate	156	25
Januvia	Sitagliptin Phosphate	149	14
Paroxetine Hcl	Paroxetine Hcl	149	14
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	148	36
Montelukast Sodium	Montelukast Sodium	146	31
Propranolol Hcl	Propranolol Hcl	143	11
Glimepiride	Glimepiride	142	14
Farxiga	Dapagliflozin Propanediol	139	30
Insulin Lispro Kwikpen U-100	Insulin Lispro	138	27
Ondansetron Hcl	Ondansetron Hcl	135	70
Hydrochlorothiazide	Hydrochlorothiazide	134	38
Albuterol Sulfate Hfa	Albuterol Sulfate	133	66
Isosorbide Mononitrate Er	Isosorbide Mononitrate	129	15
Pravastatin Sodium	Pravastatin Sodium	128	16
Pentoxifylline	Pentoxifylline	123	suppressed
Spironolactone	Spironolactone	121	14
Linzess	Linaclotide	118	12
Divalproex Sodium	Divalproex Sodium	112	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	110	suppressed
Lamotrigine	Lamotrigine	109	suppressed
Glipizide	Glipizide	106	33
Triamcinolone Acetonide	Triamcinolone Acetonide	106	53
Zafirlukast	Zafirlukast	106	suppressed
Bethanechol Chloride	Bethanechol Chloride	105	suppressed
Ozempic	Semaglutide	104	18
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	102	32
Metformin Hcl Er	Metformin Hcl	101	23
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	98	20
Pregabalin	Pregabalin	97	23
Atenolol	Atenolol	95	25
Entresto	Sacubitril/Valsartan	93	14
Fluticasone Propionate	Fluticasone Propionate	92	48
Isosorbide Dinitrate	Isosorbide Dinitrate	91	suppressed
Alprazolam	Alprazolam	89	25
Dicyclomine Hcl	Dicyclomine Hcl	89	18
Tradjenta	Linagliptin	88	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	88	19
Digoxin	Digoxin	86	13
Amitriptyline Hcl	Amitriptyline Hcl	80	suppressed
Ibuprofen	Ibuprofen	80	29
Methenamine Hippurate	Methenamine Hippurate	80	12
Aripiprazole	Aripiprazole	79	suppressed
Lactulose	Lactulose	79	28
Celecoxib	Celecoxib	75	16
Bumetanide	Bumetanide	74	12
Venlafaxine Hcl Er	Venlafaxine Hcl	74	18
Diclofenac Sodium	Diclofenac Sodium	73	35
Breo Ellipta	Fluticasone/Vilanterol	71	21
Oxybutynin Chloride Er	Oxybutynin Chloride	71	14
Azithromycin	Azithromycin	70	51
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	70	suppressed
Topiramate	Topiramate	69	suppressed
Ezetimibe	Ezetimibe	68	21
Metoclopramide Hcl	Metoclopramide Hcl	68	13
Trospium Chloride	Trospium Chloride	66	suppressed
Dutasteride	Dutasteride	65	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	65	14
Nystatin	Nystatin	65	37
Metolazone	Metolazone	64	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	63	15
Bupropion Hcl Sr	Bupropion Hcl	62	15
Meclizine Hcl	Meclizine Hcl	62	27
Sodium Chloride	0.9 % Sodium Chloride	62	24
Hydrocortisone	Hydrocortisone	61	suppressed
Latanoprost	Latanoprost	61	17
Lansoprazole	Lansoprazole	60	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	59	38
Enulose	Lactulose	58	15
Novolog Flexpen	Insulin Aspart	58	18
Temazepam	Temazepam	58	12
Diltiazem Hcl	Diltiazem Hcl	57	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	56	suppressed
Benazepril Hcl	Benazepril Hcl	55	suppressed
Bicalutamide	Bicalutamide	55	suppressed
Acetazolamide	Acetazolamide	53	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	53	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	52	suppressed
Methylprednisolone	Methylprednisolone	52	41
Liothyronine Sodium	Liothyronine Sodium	51	suppressed
Primidone	Primidone	51	11
Carbamazepine	Carbamazepine	49	suppressed
Prednisone	Prednisone	48	26
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	47	19
Ceftriaxone	Ceftriaxone Sodium	44	23
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	44	suppressed
Repaglinide	Repaglinide	44	suppressed
Risperidone	Risperidone	43	suppressed
Oxycodone Hcl	Oxycodone Hcl	42	suppressed
Albuterol Sulfate	Albuterol Sulfate	40	14
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	40	18
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	40	17
Amoxicillin	Amoxicillin	39	34
Ketoconazole	Ketoconazole	37	20
Terazosin Hcl	Terazosin Hcl	37	suppressed
Calcium Acetate	Calcium Acetate	36	suppressed
Chlorthalidone	Chlorthalidone	36	12
Nitroglycerin	Nitroglycerin	36	23
Clonazepam	Clonazepam	35	suppressed
Humalog Kwikpen U-100	Insulin Lispro	35	14
Insulin Aspart Flexpen	Insulin Aspart	35	suppressed
Morphine Sulfate	Morphine Sulfate	34	suppressed
Sucralfate	Sucralfate	34	11
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	34	13
Vancomycin Hcl	Vancomycin Hcl	34	suppressed
Estradiol	Estradiol	32	11
Fluconazole	Fluconazole	32	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	11
Klor-Con 10	Potassium Chloride	31	suppressed
Nystop	Nystatin	29	18
Belsomra	Suvorexant	28	suppressed
Folic Acid	Folic Acid	28	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	28	19
Betamethasone Dipropionate	Betamethasone Dipropionate	27	suppressed
Mupirocin	Mupirocin	27	12
Varenicline Tartrate	Varenicline Tartrate	27	suppressed
Metronidazole	Metronidazole	26	24
Neomycin Sulfate	Neomycin Sulfate	26	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	15
Insulin Lispro	Insulin Lispro	25	suppressed
Warfarin Sodium	Warfarin Sodium	25	11
Cilostazol	Cilostazol	24	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	24	suppressed
Meropenem	Meropenem	24	suppressed
Acetic Acid	Acetic Acid	23	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	suppressed
Memantine Hcl Er	Memantine Hcl	23	suppressed
Theophylline Er	Theophylline Anhydrous	23	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	22	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	22	suppressed
Isoniazid	Isoniazid	22	suppressed
Doxepin Hcl	Doxepin Hcl	21	suppressed
Levetiracetam Er	Levetiracetam	21	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	21	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Trimethoprim	Trimethoprim	21	suppressed
Dapagliflozin	Dapagliflozin Propanediol	20	suppressed
Loperamide	Loperamide Hcl	20	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	suppressed
Cefepime Hcl	Cefepime Hcl	19	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	19	suppressed
Levofloxacin	Levofloxacin	19	14
Lidocaine	Lidocaine	19	suppressed
Mounjaro	Tirzepatide	19	suppressed
Restasis	Cyclosporine	19	suppressed
Rybelsus	Semaglutide	19	suppressed
Santyl	Collagenase Clostridium Hist.	19	12
Arexvy	Rsvpref3 Antigen/As01e/Pf	18	18
Nitrofurantoin	Nitrofurantoin Macrocrystal	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	14
Travoprost	Travoprost	18	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	17	suppressed
Creon	Lipase/Protease/Amylase	16	suppressed
Daptomycin-0.9% Nacl	Daptomycin In 0.9 % Sod Chlor	16	suppressed
Dextrose 5%-0.9% Nacl	Dextrose 5 % And 0.9 % Nacl	16	12
Acetazolamide Er	Acetazolamide	15	suppressed
Azelastine Hcl	Azelastine Hcl	15	suppressed
Calcitriol	Calcitriol	15	suppressed
Dexamethasone	Dexamethasone	15	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	15	suppressed
Lagevrio (Eua)	Molnupiravir	15	13
Nyamyc	Nystatin	15	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	14	suppressed
Diltiazem 24hr Er (La)	Diltiazem Hcl	14	suppressed
Fenofibrate	Fenofibrate,micronized	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Lidocaine Hcl	Lidocaine Hcl	14	11
Vitamin D2	Ergocalciferol (Vitamin D2)	14	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	13	suppressed
Humalog	Insulin Lispro	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Nebivolol Hcl	Nebivolol Hcl	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Torsemide	Torsemide	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Valsartan	Valsartan	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Divalproex Sodium Er	Divalproex Sodium	12	suppressed
Ertapenem	Ertapenem Sodium	12	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	12	suppressed
Methotrexate	Methotrexate Sodium	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Timolol Maleate	Timolol Maleate	12	suppressed
Anastrozole	Anastrozole	11	suppressed
Colchicine	Colchicine	11	suppressed
Constulose	Lactulose	11	suppressed
Dipyridamole	Dipyridamole	11	suppressed
Lacosamide	Lacosamide	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Lurasidone Hcl	Lurasidone Hcl	11	suppressed
Mirabegron Er	Mirabegron	11	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Novolog	Insulin Aspart	11	suppressed
Ramipril	Ramipril	11	suppressed
Verapamil Hcl	Verapamil Hcl	11	suppressed
Xifaxan	Rifaximin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$136.08 · 7 records	GlaxoSmithKline, LLC.	AREXVY, JARDIANCE, Kerendia, Leqembi, TRELEGY ELLIPTA	5	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Arexvy play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error